Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

@article{Tanaka2011Antiinterleukin6RA,
  title={Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.},
  author={Toshio Tanaka and Masashi Narazaki and Tadamitsu Kishimoto},
  journal={FEBS letters},
  year={2011},
  volume={585 23},
  pages={3699-709}
}
Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases… CONTINUE READING